| Literature DB >> 33425372 |
Romain Huvé1, Pascal Fontaine1, Marie-Claude Blais1, Bérénice Conversy1.
Abstract
CASEEntities:
Keywords: Systemic lupus erythematosus; antinuclear antibodies; mast cells; vasculitis
Year: 2020 PMID: 33425372 PMCID: PMC7758563 DOI: 10.1177/2055116920979271
Source DB: PubMed Journal: JFMS Open Rep ISSN: 2055-1169
Figure 1Oral ulcers at (a) admission and (b) 1 week after discharge
Figure 2Paronychia at admission
Figure 3Thoracic radiographs of the kitten showing a moderate diffuse interstitial pattern worse in the caudodorsal region with a slight reticulated texture. Left (a) lateral and (b) dorsoventral views
Figure 4Normal thoracic radiographs of the cat 7 months after discharge. Left (a) lateral and (b) dorsoventral views
Prevalence of clinical signs of previously reported cats with systemic lupus erythematosus in decreasing order of frequency
| Studies | n | Renal disorders | Cutaneous lesions | Anemia | Polyarthritis | Fever | Lymphadenopathy/splenomegaly | Oral ulcers | Neurologic disorders | Thrombocytopenia | Leukopenia | Myositis/myocarditis | APA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Slauson et al.[ | 1 | 1 | |||||||||||
| Heise et al.[ | 1 | 1 | 1 | 1 | |||||||||
| Scott et al.[ | 2 | 2 | 2 | 2 | 1 | 2 | |||||||
| Faircloth and Montgomery[ | 1 | 1 | 1 | 1 | 1 | ||||||||
| Scott[ | 5 | 4 | 4 | 1 | |||||||||
| Gabbert[ | 1 | 1 | 1 | 1 | 1 | ||||||||
| Bennett and Nash[ | 2 | 2 | 2 | 2 | 1 | 1 | |||||||
| Pedersen and Barlough[ | 11 | 8 | 2 | 3 | 7 | 2 | 3 | 2 | 5 | 1 | |||
| Day[ | 1 | ||||||||||||
| Vitale at al.[ | 1 | 1 | 1 | 1 | |||||||||
| Lusson et al.[ | 1 | 1 | 1 | 1 | |||||||||
| Hanna[ | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 1 | |||||
| Total (%) | 30 | 17 (57) | 12 (40) | 12 (40) | 12 (40) | 12 (40) | 8 (27) | 7 (23) | 6 (20) | 4 (13) | 3 (10) | 2 (7) | 1 (3) |
APA = antiphospholipid antibodies
Antinuclear antibody (ANA) monitoring of previously reported cats with systemic lupus erythematosus (SLE) and our cat
| ANA titration with: | Unknown substrate | Hep-2 cell lines or liver
substrate | Hep-2 cell lines substrate | Liver substrate | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1[ | Case 2[ | Case 3[ | Case 4[ | Case 5[ | Case 6[ | Case 7[ | Study cat | |||||||||
| Week post-diagnosis | CS | No CS | CS | No CS | CS | No CS | CS | No CS | CS | No CS | CS | No CS | CS | No CS | CS | No CS |
| 0 | Pos 1:10 | Pos 1:40 | Pos | Pos | Pos 1:40 | Pos 1:1280 | Pos | Pos | ||||||||
| 2 | Pos 1:40 | Pos | Pos 1:320 | |||||||||||||
| 4 | Pos | Neg | ||||||||||||||
| 6 | Pos | |||||||||||||||
| 8 | Neg | Pos | ||||||||||||||
| 12 | Neg | Pos 1:40 | Pos | Pos | ||||||||||||
| 16–22 | Pos 1:10 | Neg | Neg | Neg | ||||||||||||
| 24–32 | Neg | Neg | Neg[ | Pos | ||||||||||||
| 40–50 | Neg | Neg | Pos | |||||||||||||
| 52 | Pos | |||||||||||||||
| 240 | Neg | |||||||||||||||
Discrepancy between ANA titer and SLE clinical activity
CS = clinical signs; Pos = positive; Neg = negative